High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis
Status:
Withdrawn
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if high-dose cyclophosphamide followed by a
maintenance dose of glatiramer acetate is safe in patients with relapsing remitting multiple
sclerosis (MS). The investigators hypothesize that institution of glatiramer acetate
treatment following high-dose cyclophosphamide treatment will extend the period of disease
free activity and further reduce the disability in patients with relapsing remitting multiple
sclerosis. The investigators plan to investigate the properties of glatiramer acetate against
the recurrence of MS disease activity following high dose cyclophosphamide induced cessation
detectable autoimmunity. The investigators hypothesize that glatiramer acetate, given in the
phase of immune reconstitution after high-dose cyclophosphamide, may bias the immune system
to a more tolerated state, thus leading to more stable and potentially permanent remissions.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center